Assessing risk factors of falls in cancer patients with chemotherapy-induced peripheral neurotoxicity

Bruna, Jordi; Anastopoulou, Garifallia G; Velasco, Roser; Litsardopoulos, Pantelis; Kalofonos, Haralabos

doi:10.1007/s00520-019-05023-5

Cited by 22 publications

(17 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common chemotherapy-induced toxicities; it can manifest in symptoms such as paresthesia, hyperalgesia, and allodynia 2,3 . CIPN can persist long after chemotherapy completion with patients experiencing pain, sensory loss, poor dexterity, and gait disturbance that significantly worsen quality of life, impact daily functions, and increase fall risks [4][5][6][7] . Currently, there are very limited treatment options for CIPN; additional treatments are needed 8 .…”

Section: Introductionmentioning

confidence: 99%

Health-Related Quality of Life in Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy: A Randomized Clinical Trial

et al. 2021

View full text Add to dashboard Cite

Background. Chemotherapy-induced peripheral neuropathy (CIPN) is a common, debilitating adverse effect of neurotoxic chemotherapy that significantly worsens cancer survivors' quality of life. Materials and Methods. Solid tumor survivors with persistent moderate-to-severe CIPN defined as numbness, tingling, or pain rated ≥4 on an 11-point numeric rating scale (NRS) were randomized in a 1:1:1 ratio to eight weeks of real acupuncture (RA) versus sham acupuncture (SA) versus usual care (UC). We previously reported the primary endpoint (NRS); here we report health-related quality of life endpoints: Functional

show abstract

Section: Introductionmentioning

confidence: 99%

Health-Related Quality of Life in Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy: A Randomized Clinical Trial

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The chronic form of OXAIPN was defined as a clinical syndrome characterized by a dose-related, persistent (at least two subsequent cycles without a "symptoms free" interval), symmetrical distal painful or non-painful paresthesia and dysesthesia. 15 The incidence and severity of the chronic, cumulative OXAIPN was graded by means of the seven-item composite Total Neuropathy Score-clinical version (TNSc). 16 Briefly, TNSc classified the OXAIPN severity as grade I (scores 1-7); grade II (scores 8-14); grade III (scores 15-21); and grade IV (scores >21), as previously described.…”

Section: Methodsmentioning

confidence: 99%

“…grade 1 OXAIPN in two patients (8%), grade 2 in 19 patients (76%), and grade 3 neuropathy in 4 (16%) patients Worsening of pre-existing OXAIPN was documented in seven (28%) patients and was significantly associated with higher OXA delivered cumulative dose (P < .001). Median TNSc scores following treatment (10; range [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18] were significantly increased (P < .001), when compared to the scores recorded at the end of first line treatment (8; range [2][3][4][5][6][7][8][9][10][11][12]. Rechallenging OXA appears to relatively worsen the severity of existing OXAIPN.…”

mentioning

confidence: 85%

Oxaliplatin rechallenge in metastatic colorectal cancer patients with clinically significant oxaliplatin‐induced peripheral neurotoxicity

Kalofonou

Litsardopoulos

Anastopoulou

2020

J Peripheral Nervous Sys

Self Cite

View full text Add to dashboard Cite

We investigated whether rechallenge with oxaliplatin (OXA) can worsen the preexisting oxaliplatin-induced peripheral neurotoxicity (OXAIPN) in metastatic colorectal cancer (mCRC) patients. Patients previously treated with OXA, having clinically significant grade 1 or 2 OXAIPN were assessed, after receiving rechallenge with OXA, using the clinical version of the Total Neuropathy Score (TNSc). Peripheral neuropathy was assessed at the end of first OXA exposure and at completion of OXA rechallenge. The first line OXA-based chemotherapy was completed at least 9 months earlier (OXA-free interval). We studied 25 mCRC patients, 14 males and 11 females, with a median age of 63 (35-77) years. After their first exposure to OXA-based chemotherapy, 9 (36%) patients developed grade 1 OXAIPN and 16 patients grade 2 (64%) neurotoxicity. OXA reintroduction with a median of 10 (8-14) cycles led to

show abstract

“…Biomarker studies are currently underway to identify genetic predictors for neuropathy development [ 13 ]. Recognition of CIPN is important as approximately 17.2% of patients with CIPN is estimated to have fallen at the completion of chemotherapy [ 15 ]. Both pharmacologic and non-pharmacologic treatment options have been explored in prevention and treatment of CIPN.…”

Section: Multi-organ Compromisementioning

confidence: 99%

Safety, Precautions, and Modalities in Cancer Rehabilitation: an Updated Review

Zheng

Mixon

McLarney

2021

Curr Phys Med Rehabil Rep

View full text Add to dashboard Cite

Purpose of Review Providing rehabilitation to patients with cancer can be challenging due to the medical complexity associated with the illness and its treatments. This article provides the reader with a summary of frequently encountered medical conditions in the cancer population and associated safety considerations and precautions. An update on treatment modalities commonly used for symptom management is also presented. Recent Findings Cancer and cancer treatments can cause changes in multiple organ systems. Special considerations and precautions are necessary to provide safe and effective rehabilitation. Physical modalities can be used as monotherapy or adjunct to treatment for common cancer-related side effects with recent studies noting benefit with a variety of modalities. Summary Detailed assessment of the cancer patient is necessary before implementing a rehabilitation program. Understanding cancer and side effects of treatments, including newer options, are necessary to provide safe care.

show abstract

Assessing risk factors of falls in cancer patients with chemotherapy-induced peripheral neurotoxicity

Cited by 22 publications

References 15 publications

Health-Related Quality of Life in Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy: A Randomized Clinical Trial

Health-Related Quality of Life in Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy: A Randomized Clinical Trial

Oxaliplatin rechallenge in metastatic colorectal cancer patients with clinically significant oxaliplatin‐induced peripheral neurotoxicity

Safety, Precautions, and Modalities in Cancer Rehabilitation: an Updated Review

Contact Info

Product

Resources

About